Novartis is building a new radioligand plant in China

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hiya. Today, we explore how traditionally underserved sickle cell patients became early recipients of a futuristic gene-editing therapy, see another generative AI drug discovery deal forged, and more.

The need-to-know this morning

• Roche is paying $2.7 billion for Carmot Therapeutics, a privately held company developing treatments for obesity.
• Eyepoint Pharmaceuticals saw its share price nearly quadruple in pre-market trading after its treatment for macular degeneration met its goals in a Phase 2 study.
• The FDA approved Eli Lilly’s Jaypirca as a treatment for chronic lymphocytic leukemia, widening its availability beyond mantle cell lymphoma.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In